Marker Therapeutics, Inc. income statement MRKR

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Marker Therapeutics, Inc. reported revenue of $3.5 million, down 46.2% from the year before. It recorded a net loss of $12.2 million. The operating loss came to $12.9 million, an operating margin of -363.5%. Diluted earnings per share were -$0.79. Over the twelve months ended Mar 31, 2026, revenue was $3.9 million and the net loss was $10.9 million. Across the 8 fiscal years shown, revenue grew from $205,994 in fiscal 2018 to $3.5 million in fiscal 2025, about 50.2% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Mar 31, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	4 -30.7%	4 -46.2%	7 +99.1%	3 -5.8%	4 +183.0%	1 +166.0%	0 +118.9%	0 +3.5%	0	—	—
Research and development	12 -18.0%	12 -12.4%	13 +29.3%	10 -13.0%	12 -56.9%	28 +47.2%	19 +47.9%	13 +60.5%	8 +51.5%	5 +38.2%	4 +122.1%
Selling, general and administrative	4 -7.9%	4 -1.3%	4 -43.3%	7 -34.1%	11 -12.3%	13 +23.4%	10 +5.0%	10 -59.1%	24 +280.2%	6 +36.7%	5 +5.5%
Operating income	-12 +11.3%	-13 -15.9%	-11 +23.7%	-15 +26.3%	-20 +49.9%	-39 -36.7%	-29 -28.2%	-23 +84.8%	-148 -1190.7%	-11 -35.2%	-8 -37.9%
Pretax income	—	-12 -14.0%	-11 +23.9%	-14	—	—	—	—	—	—	—
Income tax	—	-0 -130.3%	0 +1259.3%	0	—	—	—	—	0	0	0
Net income	-11 +14.8%	-12 -13.3%	-11 -30.3%	-8 +72.5%	-30 +28.5%	-42 -45.9%	-29 -34.0%	-21 +85.5%	-148 -1247.3%	-11 -347.3%	-2 +92.8%
Basic EPS	-0.63 +53.1%	-0.79 +33.6%	-1.19 -26.6%	-0.94 +73.7%	-3.58 +34.6%	-5.47	—	—	—	-1.16 -222.2%	-0.36
Diluted EPS	-0.63 +53.1%	-0.79 +33.6%	-1.19 -26.6%	-0.94 +73.7%	-3.58 +34.6%	-5.47	—	—	—	-1.16 -61.1%	-0.72
Weighted average shares, basic	17 +81.9%	15 +70.5%	9 +1.9%	9 +5.5%	8 +9.2%	8 -83.7%	47 +3.2%	46 +138.8%	19 +102.0%	9 +37.2%	7
Weighted average shares, diluted	17 +81.9%	15 +70.5%	9 +1.9%	9 +5.5%	8 +9.2%	8	—	—	—	9 +27.4%	7
Other measures
Depreciation and amortization	—	—	—	—	3 +29.8%	2 +342.5%	0 +362.0%	0	—	—	—
EBITDA	—	—	—	—	-17 +54.5%	-37 -31.4%	-28 -26.7%	-22	—	—	—
Margins
Operating margin	-303.99%	-363.45%	-168.69%	-440.37%	-563.28%	-3,179.32%	-6,188.25%	-10,567.28%	-71,930.07%	—	—
Pretax margin	—	-343.39%	-162.06%	-424.09%	—	—	—	—	—	—	—
Profit margin	-275.92%	-342.96%	-162.82%	-248.76%	-851.87%	-3,372.68%	-6,149.74%	-10,050.92%	-71,826.32%	—	—
EBITDA margin	—	—	—	—	-483.90%	-3,006.26%	-6,084.21%	-10,517.97%	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: MRKR (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Houston, TX
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1094038
Former names: TAPIMMUNE INC. (until Oct 17, 2018); TAPIMMUNE INC (until Jun 29, 2017); GENEMAX CORP (until Jun 28, 2007); EDUVERSE COM (until Jun 17, 2002)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.